{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:32:43Z","timestamp":1778841163933,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck, LLC","doi-asserted-by":"publisher","award":["20130520"],"award-info":[{"award-number":["20130520"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bluebird Bio"},{"name":"Acorda Therapeutics"},{"name":"Insys Therapeutics"},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001771","name":"Tuberous Sclerosis Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Today's and Tomorrow's Children Fund"},{"DOI":"10.13039\/100000090","name":"Department of Defense\/Congressionally Directed Medical Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01NS082320"],"award-info":[{"award-number":["U01NS082320"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P20NS080199"],"award-info":[{"award-number":["P20NS080199"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01NS082649"],"award-info":[{"award-number":["R01NS082649"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Epilepsy Therapy Project"},{"DOI":"10.13039\/100001244","name":"Milken Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001244","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hughes Family Foundation"},{"name":"Elsie and Isaac Fogelman Endowment"},{"DOI":"10.13039\/501100003769","name":"Eisai, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Insys Therapeutics"},{"name":"GW Pharmaceuticals"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R34MH089299"],"award-info":[{"award-number":["R34MH089299"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.yebeh.2016.01.012","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T15:03:33Z","timestamp":1456239813000},"page":"29-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"PA","title":["A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience"],"prefix":"10.1016","volume":"57","author":[{"given":"Madeline D.","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2016.01.012_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1535-7511.2006.00100.x","article-title":"Infantile spasms: little seizures, big consequences","volume":"6","author":"Shields","year":"2006","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1528-1157.1984.tb04195.x","article-title":"Hypsarrhythmia: variations on the theme","volume":"25","author":"Hrachovy","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0015","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1528-1167.2011.03127.x","article-title":"The effect of lead time to treatment and of age of onset on developmental outcome at 4years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study","volume":"52","author":"O'Callaghan","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/epi.12460","article-title":"Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone","volume":"55","author":"Hussain","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/peds.97.3.375","article-title":"High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study","volume":"97","author":"Baram","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0030","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0040","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0050","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1528-1157.2002.17801.x","article-title":"Visual field constriction in 91 Finnish children treated with vigabatrin","volume":"43","author":"Vanhatalo","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0055","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1528-1167.2008.01728.x","article-title":"Cerebral MRI abnormalities associated with vigabatrin therapy","volume":"50","author":"Pearl","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1528-1167.2008.01896.x","article-title":"Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy","volume":"50","author":"Wheless","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0065","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/dmcn.12188","article-title":"An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms","volume":"55","author":"Fong","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/jamaneurol.2013.1858","article-title":"Reversible vigabatrin-induced life-threatening encephalopathy","volume":"71","author":"Hern\u00e1ndez Vega","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0075","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1528-1167.2010.02772.x","article-title":"Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review","volume":"51","author":"Maguire","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1528-1167.2008.01961.x","article-title":"Visual fields at school-age in children treated with vigabatrin in infancy","volume":"50","author":"Gaily","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0085","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1528-1167.2009.02167.x","article-title":"Vigabatrin therapy in infantile spasms: solving one problem and inducing another?","volume":"50","author":"Wohlrab","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0090","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(99)02095-4","article-title":"Reversibility of vigabatrin-induced visual-field defect","volume":"354","author":"Versino","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s100720070096","article-title":"Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?","volume":"21","author":"Giordano","year":"2000","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0100","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/j.1528-1167.2009.02158.x","article-title":"Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life?","volume":"50","author":"Riikonen","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dmcn.12573","article-title":"Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study","volume":"57","author":"Riikonen","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0039-6257(94)90073-6","article-title":"Cortical visual impairment in children","volume":"38","author":"Good","year":"1994","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.yebeh.2016.01.012_bb0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ICU.0b013e32833f0085","article-title":"Recommendations for visual evaluations of patients treated with vigabatrin","volume":"21","author":"Sergott","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0120","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1212\/WNL.0000000000001069","article-title":"Vigabatrin retinal toxicity in children with infantile spasms: an observational cohort study","volume":"83","author":"Westall","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10633-012-9320-7","article-title":"Electroretinographic (ERG) responses in pediatric patients using vigabatrin","volume":"124","author":"Moskowitz","year":"2012","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0130","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"10.1016\/j.yebeh.2016.01.012_bb0135","unstructured":"Patient\/Parent\/Legal Guardian - Physician Agreement n.d. http:\/\/sabril.net\/hcp\/rems_forms\/forms\/patient_physician_agreement_form.aspx (accessed July 27, 2015)."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:24:16Z","timestamp":1761503056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":27,"alternative-id":["S1525505016000263"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.01.012","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}